In this notice, ‘Car-T Service’, ‘We’, ‘Us’ and ‘Our‘ refers to Car-T Service.

Subject to your acceptance of the terms herein, we process your personal data in accordance with Our Personal Data Protection Policy and Cookie Policy.

We take the privacy and security of your personal data seriously. This notice outlines the categories of personal data which We may collect about you and how We may use it.

This notice may be amended from time to time. If required, we will notify you of any changes.

What Information Do We Collect and How Do We Use It?

If you fill up an online form, or send an email to Us or ask Us to send you further information and/or to send you invitations to participate in scientific meetings, promotional events, cooperation opportunities and surveys, then We may collect and use personal data about you such as:

  • Name
  • Email address
  • Country of residence
  • Address
  • Telephone number

Technical information about your device, such as your IP address, device type, device and advertising identifiers, browser type and version, and other standard server log information

Other personal data which you voluntarily provide to Us

Such information will be used by Us in for the purpose for which you have given the information for, to administer the website, register you for any services you have signed up for and to respond to your queries or requests for information.

From time to time, We may obtain personal data voluntarily provided by you about you, for example, you may have voluntarily provided your name, occupation and email address, as part of a request for information. In this case, We use such information only to respond to your inquiry and to provide you with additional guidance. By providing Us with your personal data, you consent to Us processing this data for the purposes set out in this notice or any other purpose set out in any other notice we have issued.

Further, your Personal Data may be disclosed

as permitted or required by applicable law or regulatory requirements. In such a case, we will endeavor to disclose only the requested information under the circumstances;

to comply with valid legal processes such as search warrants, subpoenas or court orders;

as part of Car-T Service regular reporting obligations;

to protect the rights and properties of Car-T Service; orduring emergency situations or where necessary to protect the safety of a person or group of persons;

How do We Store Your Data

Your personal data will be stored for a number of years in accordance with local laws and our existing document retention policies.

How We Protect Your Information

We will protect your information under Our privacy and security policies which as far as reasonably possible, are intended to protect the security and integrity of all Our information, including your personal data.

What are Your Rights

You may contact Car-T Service at info@cartservice.org at any time to request information on how We process your personal data, access to the personal data We hold about you, data portability, to correct any mistakes or to request deletion of the same or withdraw your consent to certain types of processing of your personal data,If the requests are in breach of Our obligations under applicable laws, regulations or codes of practice, then We may not be able to comply with your request (or part of), but you may still be able to request stop using your personal information for further processing or deleting the same.

More information

If you have any questions or comments about this Privacy Statement, please send an email to【 business@cartservice.org 】Or call 【(86) 025-58287610 】.

Version dated: Feb 4, 2024

Fucaso® (Equecabtagene Autoleucel Injection)

-- The World's First Approved Fully Human CAR-T Therapy

Breakthrough fully human CAR structure
  • Full epitope of light and heavy chains binds tightly to BCMA
  • Fast dissociation, low exhaustion
  • Low immunogenicity
Durable persistence
  • Median duration of persistence time 419 days
  • 12-month sustained MRD negativity rate 81.7%
  • 12-month PFS rate 85.5%
Strong efficacy
  • ORR 98.9%
  • ≥CR rate 82.4%
  • MRD negativity rate 97.8%
Returning to life upon single-dose treatment
Excellent safety
  • No ≥ Grade 3 ICANS
  • Incidence of ≥ Grade 3
  • No movement/cognitive disorder observed No Parkinson's disease found